Newman Dignan & Sheerar Inc. Trims Stake in Merck & Co., Inc. $MRK

Key Points

• Newman Dignan & Sheerar Inc. cut its Merck stake by 34.2% in Q4, selling 15,275 shares and finishing the quarter with 29,420 shares worth about $3.10 million.
• Merck recently beat Q4 revenue and EPS estimates, set FY2026 EPS guidance of 5.00–5.15, and launched a cash tender offer for Terns Pharmaceuticals to bolster its oncology pipeline.
• Other notable moves: Franklin Street Advisors raised its Merck stake by 462.8% (adding 117,213 shares), insiders have sold roughly 320,176 shares (~$38.3M) in the past 90 days, and institutional investors own 76.07% of the stock.

Newman Dignan & Sheerar Inc. lowered its holdings in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) by 34.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 29,420 shares of the company's stock after selling 15,275 shares during the quarter. Newman Dignan & Sheerar Inc.'s holdings in Merck & Co., Inc. were worth $3,097,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. Cliftonlarsonallen Wealth Advisors LLC increased its stake in Merck & Co., Inc. by 3.6% in the 4th quarter. Cliftonlarsonallen Wealth Advisors LLC now owns 35,206 shares of the company's stock worth $3,706,000 after buying an additional 1,237 shares during the period. Sutton Place Investors LLC increased its stake in Merck & Co., Inc. by 13.7% in the 4th quarter. Sutton Place Investors LLC now owns 6,054 shares of the company's stock worth $637,000 after buying an additional 728 shares during the period. Jackson Square Capital LLC purchased a new position in Merck & Co., Inc. in the 4th quarter worth about $1,021,000. Franklin Street Advisors Inc. NC increased its stake in Merck & Co., Inc. by 462.8% in the 4th quarter. Franklin Street Advisors Inc. NC now owns 142,541 shares of the company's stock worth $15,004,000 after buying an additional 117,213 shares during the period. Finally, Woodmont Investment Counsel LLC increased its stake in Merck & Co., Inc. by 1.9% in the 4th quarter. Woodmont Investment Counsel LLC now owns 170,507 shares of the company's stock worth $17,948,000 after buying an additional 3,189 shares during the period. Hedge funds and other institutional investors own 76.07% of the company's stock.

Key Stories Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck launched a cash tender offer to buy Terns Pharmaceuticals, accelerating an acquisition that expands its oncology and hematology pipeline ahead of patent expiries for key products — a strategic move that can support future revenue. Merck Begins Tender Offer to Acquire Terns Pharmaceuticals, Inc.
• Positive Sentiment: JPMorgan and other analysts have raised price targets / reiterated Overweight views on MRK, signaling institutional confidence that Merck shares still have upside — a catalyst for buying interest. JPMorgan Chase & Co. Forecasts Strong Price Appreciation for Merck & Co., Inc. NYSE: MRK Stock
• Positive Sentiment: Merck’s recent quarterly results beat estimates, revenue grew year-over-year and the company set FY2026 EPS guidance — underpinning valuation and investor confidence in near-term fundamentals. Strong Results Lifted Merck & Co (MRK) in Q4
• Positive Sentiment: Merck is highlighted among consistent dividend stocks, which can attract income-focused and defensive investors amid market uncertainty. Is Merck & Co. (MRK) One of the Best Consistent Dividend Stocks to Buy Right Now?
• Neutral Sentiment: Merck lowered its offer price for Terns after reviewing trial data, a detail that changes deal economics and signals the firm is calibrating cost vs. risk — ambiguous for MRK shareholders (lower cash outlay vs. potential pipeline concerns). Merck Lowered Terns Pharmaceuticals Offer Price After Trial Data Review
• Neutral Sentiment: Coverage pieces are reassessing Merck’s valuation after strong price momentum; momentum supports higher multiples, but some analysts flag S&P 500 reweighting and valuation headwinds. Assessing Merck (MRK) Valuation After Strong Recent Share Price Momentum
• Neutral Sentiment: Analysis explains the Terns deal’s role in Merck’s pipeline and how it could affect S&P 500 valuation exposure — useful context but not an immediate share-mover. Merck’s NYSE: MRK Terns Deal And S&P 500 Valuation Impact Explained
• Negative Sentiment: Some intraday weakness was reported recently as the broader market improved — a reminder that short-term pullbacks can occur even with positive headlines. Merck (MRK) Stock Declines While Market Improves: Some Information for Investors
• Negative Sentiment: Commentary questioning whether Merck is overbought warns of near-term valuation risk after a big run — a potential headwind for momentum traders. Is It Too Late to Buy Costco or Merck? Are These Defensive Stocks Overbought?

Merck & Co., Inc. Stock Up 3.3%

Shares of NYSE MRK opened at $123.25 on Thursday. The company has a current ratio of 1.54, a quick ratio of 1.30 and a debt-to-equity ratio of 0.89. The stock has a market capitalization of $304.73 billion, a PE ratio of 16.93, a price-to-earnings-growth ratio of 2.44 and a beta of 0.26. The stock's fifty day simple moving average is $118.54 and its two-hundred day simple moving average is $104.06. Merck & Co., Inc. has a 12-month low of $73.31 and a 12-month high of $125.14.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last announced its earnings results on Tuesday, February 3rd. The company reported $2.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.01 by $0.03. The business had revenue of $16.40 billion for the quarter, compared to analysts' expectations of $16.19 billion. Merck & Co., Inc. had a return on equity of 44.57% and a net margin of 28.08%.The business's revenue for the quarter was up 5.0% on a year-over-year basis. During the same quarter last year, the firm earned $1.72 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 5.000-5.150 EPS. As a group, analysts expect that Merck & Co., Inc. will post 9.01 EPS for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, April 7th. Investors of record on Monday, March 16th were paid a dividend of $0.85 per share. This represents a $3.40 annualized dividend and a dividend yield of 2.8%. The ex-dividend date was Monday, March 16th. Merck & Co., Inc.'s payout ratio is 46.70%.

Insider Activity

In other Merck & Co., Inc. news, EVP Richard R. Deluca sold 37,685 shares of Merck & Co., Inc. stock in a transaction on Friday, February 6th. The shares were sold at an average price of $120.92, for a total value of $4,556,870.20. Following the transaction, the executive vice president directly owned 160,174 shares of the company's stock, valued at approximately $19,368,240.08. The trade was a 19.05% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Robert M. Davis sold 47,434 shares of Merck & Co., Inc. stock in a transaction on Wednesday, February 4th. The stock was sold at an average price of $118.04, for a total transaction of $5,599,109.36. Following the completion of the transaction, the chief executive officer directly owned 443,602 shares in the company, valued at $52,362,780.08. This represents a 9.66% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 320,176 shares of company stock worth $38,281,735 over the last 90 days. 0.13% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

MRK has been the subject of a number of research analyst reports. BMO Capital Markets raised Merck & Co., Inc. from a "market perform" rating to an "outperform" rating and lifted their target price for the company from $82.00 to $130.00 in a research report on Thursday, December 18th. Bank of America lifted their target price on Merck & Co., Inc. from $105.00 to $120.00 and gave the company a "buy" rating in a research report on Monday, December 15th. Zacks Research raised Merck & Co., Inc. from a "strong sell" rating to a "hold" rating in a research report on Tuesday, March 17th. Wolfe Research raised shares of Merck & Co., Inc. from a "peer perform" rating to an "outperform" rating and set a $135.00 price objective for the company in a research note on Thursday, January 8th. Finally, UBS Group upped their price objective on shares of Merck & Co., Inc. from $105.00 to $130.00 and gave the stock a "buy" rating in a research note on Wednesday, January 7th. One analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and seven have given a Hold rating to the company. According to data from MarketBeat, Merck & Co., Inc. has a consensus rating of "Moderate Buy" and a consensus price target of $127.59.

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.